Progrès dans la prévention du cancer

Abstrait

Cancer Immunotherapy regulation by antibodies

Gerald C Hsu

Radio-immunotherapy with 131I-labelled and 90Y-labelled CD20 conjugates has also shown improved response rates and progression-free survival in patients with NHL. Interestingly, antibody drug or antibody toxin conjugates have been shown to have high potency in haematological malignancies, and there have been two approved by the FDA, gemtuzumab ozogamicin in elderly patients with CD33-positive AML and, more recently, brentuximab vedotin in patients with CD30-positive Hodgkin’s lymphoma. These antibody conjugates have provided the first proof-in-principle for antibodies selectively delivering drug payloads to cancer cells, and a similar approach in patients with advanced ERBB2 positive breast cancer with the antibody drug conjugate trastuzumab emtansine.